

PEDIATRIC CANCER DATA COMMONS

Welcome to the [Pediatric Cancer Data Commons](#) quarterly newsletter! Read on for announcements from PCDC headquarters, updates from our international collaborators, and invitations to upcoming events. Past newsletters are [archived on our website](#). Please don't hesitate to [reach out with suggestions and requests](#)!

— The PCDC team



Keep in touch with us!



You're Invited

Please join us **Tuesday, April 19** at 12pm CT for [The Common Good](#), a quarterly series of thought leadership talks hosted by the PCDC.



Harnessing Collaborative Frameworks Across Consortia as Paired with Emerging National Data-driven Infrastructure to Advance Clinical Translation for Children with Brain Tumors

The Common Good welcomes **Adam Resnick, PhD**, Director of the Center for Data Driven Discovery in Biomedicine at Children's Hospital of Philadelphia and Principal Investigator of the Gabriella Miller Kids First Data Resource Center.

[Register for The Common Good](#)

Save the Date for the PCDC Annual Public Webinar!

Wednesday, May 18, 2022
9:00-11:30am Central Time

[Register for the PCDC webinar](#)

Announcements

New publication on the global pediatric cancer clinical trials landscape

A new publication led by the PCDC describes pediatric cancer clinical trial groups on the international stage with the goal of identifying the structure and function of these consortia, as well as the clinical data sources they collect, to reveal opportunities for collaborative efforts within these regions. Read the paper here: [Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage](#).

Drug development models that put children first

In January, our guest speaker series [The Common Good](#) featured Sam Blackman, founder of Day One Biopharmaceuticals, who spoke about opportunities to implement new models for pediatric oncology drug development. If you missed the talk, [you can watch it here](#). All the talks in the Common Good series are collected [on our website](#).

Presentation for Teen Cancer America

PCDC Director Sam Volchenboum presented as part of [Teen Cancer America's](#) The Monthly Drip, a series of talks for health professionals with an interest in the adolescent young adult cancer population. Watch the talk here: [Democratizing Data for Cancer Research](#).

PCDC team update

This quarter we welcomed **Maya Maric**, a Project Manager who is now working closely with the INSPIRE and Global REACH consortia. We're also happy to share that **Michael Watkins**, who was already working with us as a postdoctoral researcher, joined the team permanently as Senior Clinical Data Standards Analyst.

We're hiring!

The PCDC is growing! We invite you to share our job posting for a [Data Operations Specialist](#) with your network.




A Note from the SAC Co-Chairs

We are happy to have been selected as the co-chairs of the [PCDC Scientific Advisory Committee](#), which launched last November. The SAC convened in March with a focus on two topics. First, we reviewed the nominees for the PCDC External Advisory Board, which will launch in the coming months. Next, we introduced an important topic to all of us: protecting the privacy of patients with data in the PCDC. Discussion focused on preventing potential re-identification of data by implementing minimum bin sizes for PCDC data exploration tools. We look forward to keeping you updated in future newsletters as this discussion and other SAC activities progress.

— SAC co-chairs: Jamie Flerlage and Daisuke Tomizawa

Disease Group Milestones

The PCDC Consortium is currently composed of ten individual disease groups, each in its own stage of development. Stay informed about the accomplishments of each disease group and see what your colleagues across the globe are working on!



Data commons progress as of April 2022. [Learn more about these milestones here.](#)

ALL

- The ALL group now has two committed data contributors: Dana-Farber Cancer Institute and COG.
- Work to map clinical trials forms to data dictionaries is underway.

AML (INTERACT)

- AML data is expected soon, as harmonization by contributing groups continues to progress.

Bone Tumors (HIBISCUS)

- The HIBISCUS Executive Committee has finalized updates for the international OS data dictionary.
- Rosters have been created for work groups.

CNS Tumors (INSPIRE)

- INSPIRE continues to focus on creating an embryonal tumors data dictionary and executing data contributor agreements.
- Discussions have begun regarding the creation of diagnosis- and specialty-focused work groups.

Germ Cell Tumors (MaGIC)

- The MaGIC Annual Meeting will take place from May 22-25, with a goal to have at least five datasets stood up in the Commons by that date.

Hodgkin Lymphoma (NODAL)

- COG and St. Jude are harmonizing data for transmission to the PCDC.
- NODAL is creating charges for clinical work groups.
- The NODAL data dictionary was published by the NCI.

Neuroblastoma (INRG)

- There are now 24,655 patients' data in the Commons, with thanks to SIOPEN, Japan, GPOH, and COG for all their work that went into the trials and the harmonization of the data.

Predisposition (C3P)

- The C3P Memorandum of Understanding was signed by all seven data contributors.

Retinoblastoma (Global REACH)

- The PCDC worked with the [Cancer Research Foundation](#) to deliver funding to Grupo de America Latina de Oncologia (GALOP) to support including retinoblastoma clinical trial data from Latin America in the Commons.
- Retinoblastoma data dictionary and governance work continue, with a focus on analyzing resource needs.

Soft Tissue Sarcoma (INSTRuCT)

- A new INSTRuCT paper was published in *The Lancet Child & Adolescent Health*: [Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas](#).

Thanks for reading!

We'll be with another newsletter next quarter. In the meantime, [let us know your questions and feedback](#). We look forward to working together to transform pediatric cancer research!

—The UChicago PCDC Team